中国生物制药“得福组合”击败K药、替雷利珠单抗 国产创新药也成“头对头”挑战对象

每日经济新闻
02 Jun

又一款国产创新药物“打败”了全球“药王”帕博利珠单抗(K药)。  近日,2025年美国临床肿瘤学会(ASCO)年会在芝加哥拉开帷幕。当地时间6月1日,港股龙头药企中国生物制药(HK01177)的“得福组合”(贝莫苏拜单抗注射液+盐酸安罗替尼胶囊)一线治疗PD-L1阳性晚期非小细胞肺癌的III期临床研究(CAMPASS研究)数据以大会最高等级的LBA(Late-Breaking Abstract)...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10